Literature DB >> 24716499

Review of psychotherapeutic interventions on depression in cancer patients and their impact on disease progression.

Ingrid Barrera1, David Spiegel.   

Abstract

Depression, ranging from mild to severe, is the most frequently found psychological symptom among individuals with cancer. Depression in cancer patients has been known to mitigate emotional distress, quality of life, adherence to medical treatment, and overall health outcomes. Specifically, depression has been associated with impaired immune response and with poorer survival in patients with cancer. Various studies have found that psychotherapeutic interventions are effective in reducing symptoms of depression, which in turn could affect disease progression and mortality. This paper provides updated information on psychotherapeutic interventions geared towards cancer patients suffering from depressive disorders, and its impact on disease progression. PubMed, Cochrane Library database, PsycINFO and PsycARTICLES databases were searched from January 1980 through August 2013 using key words: psychotherapy, treatment, oncology, cancer, psycho-oncology, psychosocial issues, psychosocial stress, depression, mood disorder, and psychoneuroimmunology.

Entities:  

Mesh:

Year:  2014        PMID: 24716499     DOI: 10.3109/09540261.2013.864259

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  17 in total

1.  Developing a clinical pathway for the identification and management of anxiety and depression in adult cancer patients: an online Delphi consensus process.

Authors:  Joanne M Shaw; Melanie A Price; Josephine M Clayton; Peter Grimison; Tim Shaw; Nicole Rankin; Phyllis N Butow
Journal:  Support Care Cancer       Date:  2015-04-23       Impact factor: 3.603

2.  Psychosocial outcomes of an electronic self-report assessment and self-care intervention for patients with cancer: a randomized controlled trial.

Authors:  Jesse R Fann; Fangxin Hong; Barbara Halpenny; Traci M Blonquist; Donna L Berry
Journal:  Psychooncology       Date:  2016-09-15       Impact factor: 3.894

Review 3.  [Comorbid depressive and anxiety disorders in patients with cancer].

Authors:  H-P Kapfhammer
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

4.  Sarcopenia is an independent risk factor for depression in patients with advanced lung cancer.

Authors:  Dinglong Xue; Ning Li; Lijun Li; Yaru Huang; Kaiya Men; Qingwei Meng; Shuai Zhang
Journal:  Support Care Cancer       Date:  2022-10-06       Impact factor: 3.359

5.  Reliability and Validity of the Newly Diagnosed Breast Cancer Stress Scale in the Greek Population.

Authors:  Maria Charalampopoulou; Konstantinos Syrigos; Evaggelos Filopoulos; Vasileios Megalooikonomou; Dimitrios Vlachakis; George Chrousos; Christina Darviri
Journal:  J Mol Biochem       Date:  2020-12-30

Review 6.  Advancing psychosocial care in cancer patients.

Authors:  Luigi Grassi; David Spiegel; Michelle Riba
Journal:  F1000Res       Date:  2017-12-04

Review 7.  Psychosocial challenges for patients with advanced lung cancer: interventions to improve well-being.

Authors:  Rebecca H Lehto
Journal:  Lung Cancer (Auckl)       Date:  2017-07-28

8.  Psychometric Properties of the Chinese Version of the Arabic Scale of Death Anxiety.

Authors:  Qi Qiu; Shengyu Zhang; Xiang Lin; Chunxia Ban; Haibo Yang; Zhengwen Liu; Jingrong Wang; Tao Wang; Shifu Xiao; Ahmed M Abdel-Khalek; Xia Li
Journal:  Shanghai Arch Psychiatry       Date:  2016-06-25

9.  Increased risk of major depression subsequent to a first-attack and non-infection caused urticaria in adolescence: a nationwide population-based study.

Authors:  Chia-Lun Kuo; Chi-Yen Chen; Hui-Ling Huang; Wen-Liang Chen; Hua-Chin Lee; Chih-Yu Chang; Chu-Chung Chou; Shinn-Ying Ho; Han-Ping Wu; Yan-Ren Lin
Journal:  BMC Pediatr       Date:  2014-07-11       Impact factor: 2.125

10.  From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC).

Authors:  Zoltan Lohinai; Peter Dome; Zsuzsa Szilagyi; Gyula Ostoros; Judit Moldvay; Balazs Hegedus; Balazs Dome; Glen J Weiss
Journal:  PLoS One       Date:  2016-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.